Cohance Lifesciences Limited announced a significant leadership transition following its Board meeting. The company has appointed Umang Vohra, former CEO of Cipla Limited, as Executive Chairman effective May 1, and Group Chief Executive Officer effective May 20.

Leadership Transition Details

The Board accepted the resignation of Mr. Vivek Sharma as Executive Chairman and Director of the Company, effective from the close of business hours on April 30. Mr. Sharma tendered his resignation due to personal reasons. Following his resignation, Mr. Sharma will continue to provide services to the Company in the role of Special Advisor for a period of nine months to help transition the business effectively.

Strategic Leadership Appointment

The appointment of Mr. Vohra reflects a deliberate, strategic decision by the Board to bring in a leader whose profile is specifically suited to the company's transformation and next phase of growth. Mr. Vohra is one of the most accomplished leaders in the pharmaceutical industry with a career spanning more than three decades. As former CEO and Managing Director of Cipla Limited, he led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise.

Mr. Vohra commented on his appointment: "I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation."

Employee Stock Option Plan

The Board approved the adoption of the Cohance Lifesciences Limited – Employee Stock Option Plan in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations. The plan covers 25,918,613 employee stock options, each convertible into one equity share of face value INR 1.00 each, representing 6.25% of the fully diluted equity share capital.

The exercise price per option shall not be less than INR 325.00 per share, which represents a 2.50% discount to the average market price over the last 21 trading days prior to the Board's approval. The Company will restrict outstanding grants under the existing ESOP to not more than 1.50% of share capital on a fully diluted basis.

Company Platform and Future Direction

Cohance Lifesciences has built a differentiated position in the global CDMO landscape through its depth in proprietary chemistry, complex multi-step synthesis, and advanced process R&D. The company's capabilities span complex APIs, ADCs and Oligonucleotides, complex intermediates, performance materials and specialty ingredients. With integrated R&D centres, over 400 R&D scientists, and established partnerships with global pharmaceutical innovators, the platform is anchored in science.

Pankaj Patwari, Managing Director at Advent, stated: "The platform will greatly benefit from a leader like Umang, who brings an owner-manager mindset, and who can build on the business's scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture."

Cohance lifesciences Limited has responded to BSE's inquiry regarding the recent surge in trading volume of its shares, confirming that the movement is purely market-driven with no underlying material developments.

Regulatory Compliance Confirmation

In a filing dated April 13, 2026, the company addressed BSE's email seeking clarification on the increased volume of shares traded across exchanges. The pharmaceutical company provided comprehensive assurance regarding its compliance with disclosure requirements.

No Material Information Pending

Cohance Lifesciences explicitly confirmed that there is no pending information or announcement required to be disclosed under Regulation 30 of the SEBI Listing Regulations that could impact the price or volume behavior of the company's scrip. The management emphasized that the volume movement is attributable to prevailing market conditions rather than any specific corporate developments.

Disclosure Practices

The company reaffirmed its commitment to regulatory compliance, stating that it has been regularly notifying all Unpublished Price Sensitive Information (UPSI) as required under Regulation 30 and other applicable provisions of the SEBI Listing Regulations. This systematic approach to disclosure ensures market transparency and investor protection.

Corporate Structure

The filing was signed by Sisir K. Mishra, Company Secretary & Compliance Officer, representing Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited. The company maintains its corporate office in Hyderabad and registered office in Mumbai, continuing its operations in the pharmaceutical sector.